International audience1. Estrogen plus progestin contraceptives (EPP) are the first-line treatment of moderate hirsutism and acne in women of child bearing age (grade C). 2. CPA, 50mg/day, 20 days out of 28, associated with estrogen is the first-line treatment of "moderate to severe hirsutism" in women of childbearing age (grade C). 3. Spironolactone, given as a contraceptive, can be proposed as a second-line treatment in case of side effects or counter-indications to CPA in moderate to severe hirsutism (grade C) in women of childbearing age. No market authorization in this indication. 4. Flutamide or Finasteride are "only" to be used under the guise of contraception as a "thirdline therapy" in cases of severe hirsutism, the presence of sid...
International audienceBackground: Acne vulgaris has increased in women over the past 10 years; it cu...
Background and Objective: Acne in women can often be successfully treated by the intake of oral cont...
Introduction: Hyperandrogenism affects approximately 10-20% of women of reproductive age. Hyperandro...
International audience1. Estrogen plus progestin contraceptives (EPP) are the first-line treatment o...
Objective: To compare the efficacy of two antiandrogens, cyproterone acetate (CPA) and spironolacton...
Purpose: It is aimed to evaluate the efficiency of anti-androgenic drug therapy regiments including ...
International audienceObjective: To update the "Evaluation and Treatment of Hirsutism in Premenopaus...
PubMedID: 12866746The aim of the present study was to evaluate the effects of three different anti-a...
WOS: 000182520400004PubMed ID: 12866746The aim of the present study was to evaluate the effects of t...
Combined oral contraceptives (COCs) are considered the first-line treatment for women with hirsutism...
Objective. To identify the factors influencing the prevalence of contraception, the additional requi...
OBJECTIVE: The objective was to determine if cyproterone acetate (CPA) therapy for hirsute women dem...
The aim of this study was to compare the clinical efficacy and safety of low dose cyproterone acetat...
The aim of the present study was to evaluate the effects of three different anti-androgenic drug-the...
BACKGROUND: In recent years, several new oral contraceptives have become available. In some ways, th...
International audienceBackground: Acne vulgaris has increased in women over the past 10 years; it cu...
Background and Objective: Acne in women can often be successfully treated by the intake of oral cont...
Introduction: Hyperandrogenism affects approximately 10-20% of women of reproductive age. Hyperandro...
International audience1. Estrogen plus progestin contraceptives (EPP) are the first-line treatment o...
Objective: To compare the efficacy of two antiandrogens, cyproterone acetate (CPA) and spironolacton...
Purpose: It is aimed to evaluate the efficiency of anti-androgenic drug therapy regiments including ...
International audienceObjective: To update the "Evaluation and Treatment of Hirsutism in Premenopaus...
PubMedID: 12866746The aim of the present study was to evaluate the effects of three different anti-a...
WOS: 000182520400004PubMed ID: 12866746The aim of the present study was to evaluate the effects of t...
Combined oral contraceptives (COCs) are considered the first-line treatment for women with hirsutism...
Objective. To identify the factors influencing the prevalence of contraception, the additional requi...
OBJECTIVE: The objective was to determine if cyproterone acetate (CPA) therapy for hirsute women dem...
The aim of this study was to compare the clinical efficacy and safety of low dose cyproterone acetat...
The aim of the present study was to evaluate the effects of three different anti-androgenic drug-the...
BACKGROUND: In recent years, several new oral contraceptives have become available. In some ways, th...
International audienceBackground: Acne vulgaris has increased in women over the past 10 years; it cu...
Background and Objective: Acne in women can often be successfully treated by the intake of oral cont...
Introduction: Hyperandrogenism affects approximately 10-20% of women of reproductive age. Hyperandro...